BioSpace News Archive

De-risking and Self Advocacy Key to Changing Women’s Healthcare R&D

Despite an anticipated revenue opportunity of $24.48 billion by 2027, a fraction of R&D funding is currently allocated to this space. BioSpace spoke with Organon’s Sandy Milligan about the challenges and progress.

August 25, 2022
·
5 min read
·
Abbey Glasure
Business

Alexandra Clyde appointed to Sequana Medical Board of Directors

Sequana Medical NV, a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces the appointment of Alexandra Clyde as an independent Non-Executive Director of the Company.

August 25, 2022
·
6 min read
KU Leuven spin-off AstriVax raises € 30 million seed capital to build vaccine platform

Closing on € 30 million, AstriVax has raised the largest amount of seed capital in the history of KU Leuven spin-offs.

August 25, 2022
·
9 min read
Galderma Delivers Strong H1 2022 Results and Continued Innovation Across Its Leading Dermatology Portfolio

Particularly strong performance of Injectable Aesthetics and Dermo-cosmetics product categories with growth of 32% and 31% on a constant currency basis, respectively.

August 25, 2022
·
13 min read
BioForest

Evotec Expands Clinical and Commercial Drug Substance Manufacturing with Acquisition of Central Glass Germany

Evotec SE announced that the Company expands its clinical and commercial manufacturing platform for small molecule therapeutics by acquiring Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd.

August 25, 2022
·
4 min read
Drug Development

Oncoinvent Initiates Radspherin® Phase 2A Trial

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of cancers, announced that the first colorectal cancer patient in the RAD-18-002 phase 2A clinical trial has been treated with its drug candidate, Radspherin®.

August 25, 2022
·
2 min read
Business

Lytix Biopharma: Second quarter and first half of 2022 results

Lytix Biopharma, a Norwegian immune-oncology company, releases its second quarter and first half 2022 results - New encouraging clinical data.

August 25, 2022
·
4 min read
Business

111, Inc. Announces Second Quarter 2022 Unaudited Financial Results

111, Inc. today announced its unaudited financial results for the second quarter ended June 30, 2022.

August 25, 2022
·
21 min read
Business

BioInvent International AB: Interim Report January-June 2022

The second quarter 2022 was eventful for BioInvent, delivering a deal with the US biotech company Exelixis, positive progress in our clinical portfolio and strengthened organizational leadership.

August 25, 2022
·
3 min read
Business

AlzeCure Publishes its Interim Report for January – June 2022

AlzeCure Pharma AB announced that its interim report for the period January - June 2022 is now available on the company’s website.

August 25, 2022
·
6 min read